Category: Health Science
-
Perimeter Medical Imaging (PINK.V) successfully commercializes their breast cancer technology
In the biotech/medtech world, the steps to viability as a company are proving your technology works, getting that technology approved by the FDA, finding doctors who are interested in using it, and commercializing the product so it can be manufactured to scale. Perimeter Medical Imaging (PINK.V) just made it through the final boss level. Perimeter…
-
![Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making]()
Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making
The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If you were able to live to the age of 90 and retain either the mind or body of a 30-year-old for the last 60 years of…
-
![Aequus Pharma (AQS.V) update including Q1,2021 financial highlights]()
Aequus Pharma (AQS.V) update including Q1,2021 financial highlights
On May 31, 2021 Aequus Pharmaceuticals (AQS.V) reported financial results for Q1, 2021. Aequus is a $19 million pharmaceutical company focused on developing and commercializing high quality, differentiated products. AQS is building a Canadian commercial platform through its own development pipeline and through license-acquisition. On November 20, 2020 Equity Guru’s Chris Parry spoke with Aequus’…
-
![Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts]()
Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts
Anyone else watching charts trend downwards? Yeah. There’s a reason that junior market traders hold tight to the saying of “May: sell and go away”, but ‘May’ started unusually early this year. The biggest catalyst of course being the social upheaval that comes with different economies being at different stages of vaccination – and therefore…
-
![Cybin (CYBN.E) new tryptamine patent improves outcome quality]()
Cybin (CYBN.E) new tryptamine patent improves outcome quality
Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…
-
![Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech]()
Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to raise a considerable amount of cash while having its hands in several different buckets, bringing in $23 million CAD on a bought deal back in February. Mind…
-
![XPhyto (XPHY.C) partner will begin sale of rapid Covid-ID Lab tests in Germany next week]()
XPhyto (XPHY.C) partner will begin sale of rapid Covid-ID Lab tests in Germany next week
XPhyto Therapeutics (XPHY.C) announced their partner Max Pharma GmbH will begin to sell XPhyto’s rapid point-of-care Covid-19 PCR test system (Covid-ID Lab) in Germany next week. The Covid-ID Lab test provides quality testing for the Covid-19 virus, achieving a 95% confidence interval, and delivering results within 25 minutes. Covid-ID Lab is registered within the European…
-
![Delic (DELC.C) acquisition target completes $3.43 million private placement]()
Delic (DELC.C) acquisition target completes $3.43 million private placement
Delic Holdings (DELC.C) announced that their acquisition target, Complex Biotech Discovery Venture (CBDV), has closed their previously-announced non-brokered private placement. The private placement consists of 11,441,189 CBDV Subscription Receipts sold at $0.30 each. Every subscription receipt will grant its holder one common share of CBDV and one warrant, exercisable at $0.40 for 24 months after…
-
![Bright Minds Biosciences (DRUG.C) is actually really tight]()
Bright Minds Biosciences (DRUG.C) is actually really tight
Serotonin over psychedelics Bright Minds Biosciences (DRUG.C) isn’t banking on recreational psychedelics being relevant any time soon, they aren’t selling mushroom powder, and don’t own any ketamine clinics. Rather, they are developing novel therapeutics to improve the lives of people with severe and life-altering diseases with a focus on 5-HT (serotonin) medicines. The company does…
-
Delic Holdings (DELC.C) asked to justify promo materials but, to be honest, the materials are good
At Equity.Guru, engaged as we are in market awareness programs for public companies, we often see competing entities that are more promotional than journalistic, banging out borderline insanity regarding their client companies and how they’re all the best thing ever. And when we see something egregious, we’re often the first ones to point it out.…
